Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials

被引：0
|
作者：
Treat, J.
Scagliotti, G.
Peng, G.
Monberg, M. J.
Obasaju, C. K.
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e18004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18004
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Li, Ming
    Zhang, Qian
    Fu, Peifang
    Li, Ping
    Peng, Aimei
    Zhang, Guoliang
    Song, Xiaolian
    Tan, Min
    Li, Xuan
    Liu, Yang
    Wu, Yueping
    Fan, Suyun
    Wang, Changhui
    PLOS ONE, 2012, 7 (05):
  • [22] An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
    Chang, John Wen-Cheng
    Thongprasert, Sumitra
    Wright, Elaine
    Tsang, Kenneth
    Kim, Heung Tae
    Ahn, Myung-Ju
    Kim, Joo-Hang
    Kang, Jin Hyoung
    Kim, Sang-We
    Walzer, Stefan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 13 - 21
  • [23] Comparison of bevacizumab versus pemetrexed in combination with platinum-based doublets in first-line treatment of advanced non-small cell lung cancer.
    Rodrigues Pereira, Augusto Akikubo
    Martins, Sandro Jose
    Lessa, Rafael Costa
    Ismael Pinto, Flavio Augusto
    Gagliato, Debora De Melo
    Santos, Elizabeth S.
    Ferreira Rodrigues, Newton Augusto
    Aires Freitas, Paulo Henrique
    Padua, Fernando Vidigal
    Alves, Marclesson S.
    Lima, Geraldine Eltz
    Fanelli, Marcello Ferretti
    Rinck, Jose A.
    Dettino, Aldo A.
    Nicolau, Ulisses Ribaldo
    Pereira, Jose Rodrigues
    De Sousa Cruz, Marcelo Rocha
    Lima, Vladmir C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [25] Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Santoro, Armando
    Hillerdal, Gunnar N.
    Hoeffkenc, Gert
    Favaretto, Adolfo
    Carrion, Ramon Perez
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Helsberg, Karin
    Soldatenkova, Victoria
    Bourayou, Nawel
    Sorensen, Jens B.
    LUNG CANCER, 2014, 86 (01) : 47 - 53
  • [26] The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (01) : 23 - 28
  • [27] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.
    Nagel, S.
    Groeschel, A.
    Sebastian, M.
    Andreas, S.
    Mueller, T.
    Schneller, F.
    Guetz, S.
    Leschinger, M. I.
    Buettner, H.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Clinical Observation and Prognostic Analysis of Pemetrexed plus Platinum as First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer
    Wang, Ji-Ying
    Cai, Yong
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (11) : 6267 - 6271
  • [30] Cisplatin (CDDP) plus vinorelbine (VRB) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Molecular correlates
    de las Penas, R.
    Provencio, M.
    Camps, C.
    Cobo, M.
    Massuti, B.
    Jimenez, U.
    Artal, A.
    Cardenal, F.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345